Targeting miR-21 for the therapy of pancreatic cancer

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 986-994

  Sicard, Flavie ^a,b   Gayral, Marion ^a,b   Lulka, Hubert ^a,b   Buscail, Louis ^a,b   Cordelier, Pierre ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; GEMCITABINE; LENTIVIRUS VECTOR; MICRORNA 21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MEGADOSE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA;

EID: 84877060316     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.35     Document Type: Conference Paper

References (26)

1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E and Forman, D (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Torrisani, J, Bournet, B, Cordelier, P and Buscail, L (2008). [New molecular targets in pancreatic cancer]. Bull Cancer 95: 503-512.
3. Conroy, T, Desseigne, F, Ychou, M, Bouché, O, Guimbaud, R, Bécouarn, Y et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
4. Delpu, Y, Hanoun, N, Lulka, H, Sicard, F, Selves, J, Buscail, L et al. (2011). Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 12: 15-24.
5. Iorio, MV and Croce, CM (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
6. du Rieu, MC, Torrisani, J, Selves, J, Al Saati, T, Souque, A, Dufresne, M et al. (2010). MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 56: 603-612.
7. Nair, VS, Maeda, LS and Ioannidis, JP (2012). Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 104: 528-540.
8. Pan, X, Wang, ZX and Wang, R (2010). MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 10: 1224-1232.
9. Dufau, I, Frongia, C, Sicard, F, Dedieu, L, Cordelier, P, Ausseil, F et al. (2012). Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 12: 15.
10. Chung, E, Yamashita, H, Au, P, Tannous, BA, Fukumura, D and Jain, RK (2009). Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4: e8316.
11. Sabatel, C, Malvaux, L, Bovy, N, Deroanne, C, Lambert, V, Gonzalez, ML et al. (2011). MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS ONE 6: e16979.
12. Wang, S and Olson, EN (2009). AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 19: 205-211.
13. Costello, E, Greenhalf, W and Neoptolemos, JP (2012). New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9: 435-444.
14. Jones, S, Zhang, X, Parsons, DW, Lin, JC, Leary, RJ, Angenendt, P et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
15. Yachida, S, Jones, S, Bozic, I, Antal, T, Leary, R, Fu, B et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
16. Campbell, PJ, Yachida, S, Mudie, LJ, Stephens, PJ, Pleasance, ED, Stebbings, LA et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
17. Moriyama, T, Ohuchida, K, Mizumoto, K, Yu, J, Sato, N, Nabae, T et al. (2009). MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074.
18. Ravet, E, Lulka, H, Gross, F, Casteilla, L, Buscail, L and Cordelier, P (2010). Using lentiviral vectors for efficient pancreatic cancer gene therapy. Cancer Gene Ther 17: 315-324.
19. Carrere, N, Vernejoul, F, Souque, A, Asnacios, A, Vaysse, N, Pradayrol, L et al. (2005). Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 16: 1175-1193.
20. Cordelier, P, Bienvenu, C, Lulka, H, Marrache, F, Bouisson, M, Openheim, A et al. (2007). Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Ther 14: 19-29.
21. Gentner, B, Schira, G, Giustacchini, A, Amendola, M, Brown, BD, Ponzoni, M et al. (2009). Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63-66.
22. Durand, S and Cimarelli, A (2011). The inside out of lentiviral vectors. Viruses 3: 132-159.
23. Moiani, A, Paleari, Y, Sartori, D, Mezzadra, R, Miccio, A, Cattoglio, C et al. (2012). Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122: 1653-1666.
24. Shi, L, Chen, J, Yang, J, Pan, T, Zhang, S and Wang, Z (2010). MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352: 255-264.
25. Si, ML, Zhu, S, Wu, H, Lu, Z, Wu, F and Mo, YY (2007). miR-21-mediated tumor growth. Oncogene 26: 2799-2803.
26. Park, JK, Lee, EJ, Esau, C and Schmittgen, TD (2009). Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38: e190-e199.